Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure

Bonios, Michael; Terrovitis, John; Drakos, Stavros G.; Katsaros, Fotis; Pantsios, Chris; Nanas, Serafim; Kanakakis, John; Alexopoulos, Georgios; Toumanidis, Savvas; Anastasiou-Nana, Maria; Nanas, John N.

doi:10.1016/j.ijcard.2011.03.013

Cited by 54 publications

(67 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The six included studies randomized a total of 319 enrolled patients: 207 to levosimendan and 113 to control ( Table ). Different comparators were used: placebo in three studies, standard treatment in one study, dobutamine in one study, and furosemide in one study . Three studies were multicentre …”

Section: Resultsmentioning

confidence: 99%

Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta‐analysis of randomized trials

et al. 2017

View full text Add to dashboard Cite

AimsIntermittent levosimendan administration has been suggested to improve survival in patients with advanced heart failure (AdHF). Quality of life is a key issue for AdHF patients and is negatively affected by frequent hospitalizations.Methods and resultsCENTRAL, Google Scholar, MEDLINE/PubMed, Scopus, and the Cochrane Central Register of clinical trials (updated 15/1/2017) were searched for randomized controlled trials investigating the effect of intermittent levosimendan administration in patients with AdHF. The primary outcome was the number of patients requiring rehospitalization 3 months after the end of treatment. A total of 319 patients from six trials were included. Overall pooled analysis showed that the use of levosimendan was associated with a significant reduction in the number of rehospitalizations at 3 months: 33/207 (16%) vs. 39/113 (35%), risk ratio 0.40, 95% confidence interval 0.27–0.59, P < 0.001, I 2 = 0%. This result was confirmed by sensitivity analyses.ConclusionsWithin the limitations of this meta‐analysis including also studies in which endpoints were not independently adjudicated and not clearly specified, repetitive or intermittent administration of levosimendan for patients with AdHF was associated with a reduction in the rehospitalization rate at 3 months. Large, high‐quality randomized controlled trials are needed to confirm this finding.

show abstract

Section: Resultsmentioning

confidence: 99%

Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta‐analysis of randomized trials

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Sixty-three patients with decompensated end-stage HF refractory to standard therapy were randomized by Bonios et al [44] to receive levosimendan, dobutamine, or the combination of both drugs. Patients were first treated with inotropes for stabilization, and entered the study after successful weaning from i.v.…”

Section: Clinical Studies On the Effects Of Levosimendan In Adhfmentioning

confidence: 99%

Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy

Pölzl¹,

Altenberger

Baholli

et al. 2017

International Journal of Cardiology

View full text Add to dashboard Cite

“…Die Schlaganfallrate ab dem zweiten Tag nach der Implantation beträgt 8 Ereignisse auf 100 Patientenjahre bei Patienten, die keine DeviceInfektion aufweisen [3], und das sind immerhin 98 %. Fatale Device-Infektionen finden sich bei 2 % der Patienten [4].…”

Section: Erfahrungen Weltweitunclassified

“…Medikamentös kann ihnen derzeit kein längerfristiges Behandlungskonzept angeboten werden, das Lebensqualität und Langzeitüberleben signifikant verbessern würde [3]. Signifikant bessere Überlebenschancen bieten derzeit nur chirurgische Optionen, die orthotope Herztransplantation (HTX) als biologischer Herzersatz [1,6,18] bzw.…”

unclassified

Das komplett künstliche Herz

2016

View full text Add to dashboard Cite

Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure

Cited by 54 publications

References 39 publications

Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta‐analysis of randomized trials

Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta‐analysis of randomized trials

Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy

Das komplett künstliche Herz

Contact Info

Product

Resources

About